I was at Novartis headquarters in Basel yesterday for the company’s Q4 results, and my burning question was – did the company have any designs on entering the viral vector-based gene therap
Swiss pharma giant Novartis saw modest growth of 2% in 2017, with growth in Cosentyx and Entresto offsetting generic erosion to its cancer blockbuster Gleevec/Glivec.
